Tamazyan Vahagn, Khachatryan Aleksan, Batikyan Ashot, Harutyunyan Hakob, Aryal Binit, Achuthanandan Supraja, Hollander Gerald
Department of Internal Medicine, Maimonides Medical Center, Brooklyn, USA.
Department of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, USA.
Cureus. 2025 Jun 5;17(6):e85387. doi: 10.7759/cureus.85387. eCollection 2025 Jun.
Sepsis-induced new-onset atrial fibrillation (NOAF) is a frequent and serious complication in critically ill patients, linked to increased morbidity, mortality, stroke, and prolonged hospitalization. Though often transient during acute illness, NOAF is now recognized as a predictor of long-term cardiovascular vulnerability, with recurrence rates exceeding 50% over five years and a significantly heightened risk of thromboembolic events. Stroke risk is notably elevated in this population, yet the role of anticoagulation remains uncertain due to potential bleeding complications and lack of clear guidelines. This review consolidates current evidence on the pathophysiology, incidence, risk factors, and clinical impact of sepsis-induced NOAF, with a focus on stroke prevention, recurrence, anticoagulation challenges, and emerging predictive models. Additionally, it examines prevention strategies that target inflammatory and hemodynamic pathways.
脓毒症诱发的新发房颤(NOAF)是危重症患者常见且严重的并发症,与发病率增加、死亡率升高、中风及住院时间延长相关。尽管在急性疾病期间通常为短暂性发作,但NOAF现在被认为是长期心血管易损性的预测指标,五年内复发率超过50%,血栓栓塞事件风险显著增加。该人群中风风险明显升高,但由于潜在的出血并发症和缺乏明确的指南,抗凝治疗的作用仍不确定。本综述整合了关于脓毒症诱发NOAF的病理生理学、发病率、危险因素及临床影响的现有证据,重点关注中风预防、复发、抗凝挑战及新兴预测模型。此外,还研究了针对炎症和血流动力学途径的预防策略。